Atrial Fibrillation
Atrial fibrillation (AF), the most prevalent sustained cardiac arrhythmia, significantly impacts patients with heart failure, particularly those with HFpEF. The coexistence of AF and HFpEF not only compounds the risk of adverse outcomes, leading to a marked increase in hospitalizations and mortality rates but also poses a diagnostic challenge, as AF can precede the recognition of HFpEF by years. This association is further complicated by the shared risk factors driving progressive left atrial myopathy, a key factor in the development of HFpEF.
Epidemiological evidence suggests a strong link between AF and the emergence of HFpEF, with studies indicating a high prevalence of undiagnosed HFpEF among patients presenting with exertional dyspnea and AF.
Management strategies for AF in the context of HFpEF primarily involve rate or rhythm control, with pharmacological interventions often limited by side effects and contraindications.
For anesthesia providers, understanding the intricate relationship between AF and HFpEF, along with the challenges in managing these conditions perioperatively, is crucial. This includes recognizing the heightened risks associated with general anesthesia and the need for tailored anesthesia plans that account for the complexities of managing AF and HFpEF concurrently, ensuring optimal patient outcomes in the perioperative setting.
Arterial Hypertension
Hypertension is the predominant comorbidity in heart failure with preserved ejection fraction (HFpEF), present in about 75% of these patients. Research indicates that long-term optimal blood pressure control is crucial, with a systolic blood pressure range of 120-130 mmHg and diastolic 70-80 mmHg correlating with the lowest mortality rates. Hypertension exacerbates HFpEF by promoting myocardial remodeling and dysfunction via increased afterload and activating the renin-angiotensin-aldosterone and sympathetic nervous systems. For anesthesia providers, this highlights the importance of meticulous blood pressure management in HFpEF patients undergoing surgery, with a focus on individualized pharmacologic strategies that consider the adverse effects of hypertension.
Coronary Artery Disease
Coronary artery disease (CAD) is prevalent in over half of patients with heart failure with preserved ejection fraction (HFpEF), significantly influencing their prognosis. HFpEF patients with CAD face a higher risk of cardiovascular and sudden death compared to those with heart failure with reduced ejection fraction (HFrEF). CAD leads to decreased coronary flow reserve and myocardial oxygen supply, impairing diastolic function and prompting structural changes in the heart, such as hypertrophy and scarring. For anesthesia providers, this underscores the importance of recognizing CAD's impact on HFpEF patients and the need for meticulous perioperative assessment to prevent and mitigate cardiovascular emergencies.
Renal Dysfunction
Renal dysfunction is prevalent among patients with heart failure with preserved ejection fraction (HFpEF), affecting 20-30% of this population, leading to a reciprocal negative impact between heart and renal function. This interplay elevates cardiovascular risks and mortality, with renal blood flow and sodium excretion diminished due to increased central venous pressure from complications like pulmonary hypertension and right ventricular dysfunction. Such renal impairment exacerbates HFpEF through heightened systemic inflammation and endothelial dysfunction, driven by renal mediators including fibroblast growth factors and uremic toxins.
The coexistence of cardiac and renal insufficiency complicates the management of HFpEF, as standard heart failure medications may deteriorate renal function or are contraindicated with renal insufficiency. Anesthesia providers should be aware of the potential for mild fluctuations in renal function and the necessity for judicious medication management, particularly regarding renin-angiotensin-aldosterone system inhibitors and diuretics, especially during periods of acute renal function decline. Monitoring and maintaining electrolyte balance and renal function is crucial, with guidelines recommending a tailored approach to drug and fluid therapy.
Other Comorbidities
Patients with HFpEF frequently encounter other comorbidities that complicate their clinical management. Notably, Type 2 diabetes (T2D) is present in roughly one-third of HFpEF cases, exacerbating diastolic dysfunction and elevating the risk of death and hospital admissions. T2D triggers myocardial alterations that can precipitate heart failure, even in the absence of other cardiovascular conditions. Similarly, sleep apnea—a condition affecting approximately 48% of HFpEF patients—plays a significant role in the perioperative management challenges and adverse outcomes associated with this type of heart failure. Moreover, a range of other prevalent comorbidities, including anemia, depression, obesity, hyperlipidemia, chronic obstructive pulmonary disease (COPD), sarcopenia, and pulmonary hypertension are often present. Each of these factors contribute to the complexity of HFpEF.
